Literature DB >> 35545901

Closing the hepatitis C treatment gap: United States strategies to improve retention in care.

Austin T Jones1, Christopher Briones2, Torrence Tran2, Lisa Moreno-Walton3, Patricia J Kissinger4.   

Abstract

The hepatitis C virus (HCV) treatment landscape is shifting given the advent of direct-acting antivirals and a global call to action by the World Health Organization. Eliminating HCV is now an issue of healthcare delivery. Treatment is limited by the complexity of the HCV care continuum, expensive therapy and competing health burdens experienced by an underserved HCV population. The objective of this literature review was to assess strategies to improve retention in HCV care, with particular focus on those implemented in the United States. We identified barriers in HCV care retention and propose solutions to increase HCV treatment delivery. The following recommendations are herein described: improving the cohesion of health services through localized care and integrated case management, expanding the supply of non-specialist HCV treatment providers, leveraging patient navigators and care coordinators, improving adherence through directly observed therapy and reducing cost barriers through value-based payment and pharmaceutical subscription models.
© 2022 John Wiley & Sons Ltd.

Entities:  

Keywords:  care continuum; healthcare delivery; hepatitis C; retention; treatment

Mesh:

Substances:

Year:  2022        PMID: 35545901      PMCID: PMC9276641          DOI: 10.1111/jvh.13685

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.517


  42 in total

Review 1.  Extrahepatic morbidity and mortality of chronic hepatitis C.

Authors:  Francesco Negro; Daniel Forton; Antonio Craxì; Mark S Sulkowski; Jordan J Feld; Michael P Manns
Journal:  Gastroenterology       Date:  2015-08-28       Impact factor: 22.682

2.  Alternative State-Level Financing for Hepatitis C Treatment-The "Netflix Model".

Authors:  Mark R Trusheim; William M Cassidy; Peter B Bach
Journal:  JAMA       Date:  2018-11-20       Impact factor: 56.272

3.  Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.

Authors:  Christopher Woodrell; Jeffrey Weiss; Andrea Branch; Donald Gardenier; Katherine Krauskopf; Natalie Kil; Harold Paredes; Kian Bichoupan; Keith Sigel
Journal:  J Addict Med       Date:  2015 Sep-Oct       Impact factor: 3.702

4.  The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.

Authors:  Sofia R Bartlett; Amanda Yu; Nuria Chapinal; Carmine Rossi; Zahid Butt; Stanley Wong; Maryam Darvishian; Mark Gilbert; Jason Wong; Mawuena Binka; Maria Alvarez; Mark Tyndall; Mel Krajden; Naveed Z Janjua
Journal:  Liver Int       Date:  2019-09-20       Impact factor: 5.828

5.  Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.

Authors:  M Lin; J Kramer; D White; Y Cao; S Tavakoli-Tabasi; S Madu; D Smith; S M Asch; H B El-Serag; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2017-09-26       Impact factor: 8.171

6.  Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.

Authors:  M Christopher Roebuck; Joshua N Liberman
Journal:  Am J Manag Care       Date:  2019-06       Impact factor: 2.229

7.  Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.

Authors:  Jack Gunn; Peter Higgs
Journal:  Res Social Adm Pharm       Date:  2019-04-10

Review 8.  Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Authors:  Rositsa B Dimova; Marija Zeremski; Ira M Jacobson; Holly Hagan; Don C Des Jarlais; Andrew H Talal
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

9.  A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.

Authors:  Anna Y Palmer; Amanda J Wade; Bridget Draper; Jessica Howell; Joseph S Doyle; Dennis Petrie; Alexander J Thompson; David P Wilson; Margaret E Hellard; Nick Scott
Journal:  Int J Drug Policy       Date:  2019-12-20

10.  Continuum of Care for Hepatitis C Virus Among Patients Diagnosed in the Emergency Department Setting.

Authors:  Erik S Anderson; James W Galbraith; Laura J Deering; Sarah K Pfeil; Tamara Todorovic; Joel B Rodgers; Jordan M Forsythe; Ricardo Franco; Henry Wang; N Ewen Wang; Douglas A E White
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.